Ann: Strategic Agreement Signed with RMIT, page-2

• Leading Australian research university, Royal Melbourne Institute of Technology and MGC Pharmaceuticals have signed a Binding Memorandum of Understanding to collaborate on a full suite of medicinal cannabis research initiatives, initially centred on genetics and cultivation

• Under the Binding Memorandum of Understanding (MOU), the parties have agreed to immediately negotiate terms for an umbrella agreement to undertake joint medicinal cannabis research programs at RMIT facilities that aim to include:

o The establishment of a world first “International Library of Cannabis Medicine” detailing the genetic make-up of a wide variety of cannabinoid strains​

​

o Development of genetics and breeding programs for establishing medical cannabis strains in Australia that are effective for treating specific diseases​

​

o Development of medical grade cannabis products for future clinical studies in Australia​

• MXC will apply for a Medical Cannabis Licence specifically for all cultivation and research to be undertaken at the secure RMIT facilities

• Fast tracks MXC’s path to clinical trials in Australia and partnering with one of the country’s leading scientific research institutions

• The Binding MOU substantially strengthens MGC Pharmaceuticals research credentials and its leadership position in the Australian medicinal cannabis market

• Parties to move immediately to negotiate final terms for the formal Umbrella Agreement on these joint medicinal cannabis programs in Australia